# 1. Financial Performance ## A. Key Figures * **Total Net Sales (Domestic 2025):** **₹1,511 Cr** (diabetes ~50%, partnerships ~50%) * **Profit Before Tax:** +1% (full year) · **significant drop** (quarterly) * **Profit After Tax:** +4% YoY * EBITDA Margin: 21.5% (8-quarter low) · **flat** expected for full year * **Operating Expenses:** **17% reduction** (quarter and full year) ## B. Revenue Growth * **Core Sales Dominance:** Revenue stream remains highly concentrated in product sales (92–93%), with Consumer Health services and discontinued promotions having **no profit impact**. * **Diabetes & Partnerships Drive Growth:** Domestic sales growth anchored by **robust momentum in diabetes products** and balanced contribution from partnership activities. ## C. Profit Margins * **Resilient Underlying Earnings:** Despite quarterly PBT decline, full-year profitability improved, with **profit before exceptional items up 1%** and PAT up 4%, signaling operational resilience. * **Margin Pressure Transitory:** EBITDA margin contraction to 5% attributed to **temporary phasing and stock movement effects**, not structural or partnership performance issues. * **Stable Diabetes Margins:** Segment-level profitability in diabetes held steady, though full margin breakdowns are restricted by disclosure policies. ## D. Cost Optimization * **Sustained Cost Discipline:** Operating expenses reduced by **17%** year-on-year, driven by strategic optimization and favorable partnership terms, with flat depreciation and negligible employee cost impact. --- # 2. Product & Therapy Performance ## A. Key Figures * **Insulin Portfolio Growth:** **6%** overall · **11%** analogs growth * **Lantus Market Share:** **31%** in basal insulin segment * **Toujeo & Soliqua Growth:** **Double-digit** growth for both products ## B. Diabetes Portfolio * **Core Growth Resilience:** Diabetes business delivered strong double-digit growth, with underlying partnership performance stable at **4–5%** after adjusting for inventory dynamics. * **Market Leadership Intact:** Sanofi maintains dominant **31% share** in basal insulin, with Lantus showing resilient demand despite competitive pressures from GLP-1s. ## C. Insulin Growth * **Analog Acceleration:** Portfolio benefited from market shift toward analogs, driven by **6% volume acceleration** in Lantus and strong uptake of next-gen Toujeo. * **Competitive Tailwinds:** Discontinuation of Novo Nordisk’s human insulin pens boosted analog adoption, favoring Sanofi’s portfolio with **11% analog growth**. ## D. Soliqua Performance * **Strategic Differentiation:** Soliqua is gaining traction in its second year, leveraging **fixed-dose glargine + GLP-1 combination** to target three underserved patient segments. * **Growth Without Cannibalization:** Delivering double-digit growth without impacting other brands, capitalizing on rising GLP-1 awareness and **unique profile of weight neutrality and low hypoglycemia risk**. * **Product Design:** Currently available only in **disposable pen (solo start)** format, aligning with ease-of-use trends in chronic therapy. ## E. R&D Pipeline Progress * **Late-Stage Momentum:** Multiple Phase II/III trials ongoing for **teplizumab, Brivekimig, and Frexalimab**, targeting transformative therapies in Type 1 and Type 2 diabetes. * **Strategic Focus Areas:** Cardiovascular and CNS prioritized for expansion, with **cardiovascular offering synergy potential**; no current push into unrelated therapeutic areas. --- # 3. Partnership & Sales Mix ## A. Key Figures * **Partnership Sales (FY25):** **-2%** YoY decline * **Q4 Partnership Sales:** **₹153 Cr** (vs. ~₹200 Cr in Q3) ## B. Partner Revenue Trends * **Temporary Sales Pressure:** Partnership revenue decline driven by **inventory phasing**, **frozen onboarding periods**, and **new gross-to-net adjustments**, not underlying demand. * **Stabilizing Trajectory:** Excluding one-offs and inventory swings, partnership business is growing as expected, with signs of stabilization post-volatility. * **Divergent Portfolio Performance:** OAD portfolio showed **higher single-digit H2 growth** after Emcure transition, while non-OAD portfolio grew in **low single digits**, weighed by competitive discounting in Cipla’s CV segment. ## C. Strategic Expansion & Market Access * **Tier 2/3 Growth Focus:** Partnership model remains strategic for expanding reach in underpenetrated markets, backed by dedicated teams and partner investments. * **Public Sector Momentum:** Key 2026 catalysts include **Soliqua’s public sector entry** and **Toujeo’s expanded public sector footprint**, despite no new product launches. * **Distribution Leverage:** Management views current growth as foundational, with upside from stronger partner networks (e.g., Emcure, Cipla) to drive deeper market penetration. --- # 4. Geography & Market Access ## A. Export Operations * **Headline:** Export decline driven by planned exit from Ankleshwar site, with transition to Zentiva fully completed by 2024; impact previously flagged and now behind the company. * **Headline:** Global footprint maintained via Goa facility, which supplies essential medicines to **~25 countries**, reinforcing export resilience and manufacturing credibility. ## B. NLEM Pricing Strategy * **Headline:** Public sector expansion underway with targeted outreach to CGHS, ESI, railways, defense, and state contracts, broadening access to institutional demand pools. * **Headline:** Clear pricing framework: NLEM products to grow in line with **WPI**, while non-NLEM portfolio eligible for **up to 10% price increases** per product, subject to market dynamics and approvals. --- # 5. Innovation & Technology ## A. AI-Enabled Patient Programs * **Customer-Centric Digital Transformation:** Patient support programs are being enhanced with AI and innovative journey orchestrations to improve diabetes management and adherence. ## B. Digital Insulin Pen Development * **Next-Gen Device Pipeline:** Development underway on a novel digital insulin pen with integrated AI to boost adherence and clinical outcomes. * **Reusable Soliqua Pen in Pipeline:** India is positioned as a pioneer market for a reusable Soliqua pen, currently under business case review, with potential launch in **FY '27 or FY '28**. ## C. Real-World Evidence Studies * **LANDMARC Study Completed:** Large-scale real-world evidence generated from **382 sites and nearly 6,000 patients**, with ongoing publications expected through 2024 and at the **IDF conference next year**. ## D. Clinical Trial Milestones * **Soliqua Trial Milestone Achieved:** Final patient enrolled in a Phase study evaluating Soliqua in obese adults with uncontrolled Type 2 diabetes (**105 patients, 9 sites**); results pending. * **No Near-Term Product Launches:** Sanofi India plans **no new product launches in 2026**, focusing instead on real-world evidence dissemination and study completion. * **Group-Level Strategy Clarified:** No shareholder value seen in merging listed entity with private vaccines business; vaccine launches in private segment remain under evaluation. --- # 6. Demand & Volume Trends ## A. Key Figures * **Diabetes Market Growth:** 6% * **Volume Growth (Partnered Portfolio):** +4% (ex-cert effect) * **OAD & Cardio Portfolio Growth:** 5% (single-digit) ## B. Market Growth Outlook * **Structural Demand Tailwinds:** Non-communicable diseases in India projected to grow at **double-digit rates** through 2035, underpinning long-term demand for chronic therapies. * **Underlying Growth Potential:** Absent supply disruptions, market growth could have reached **double-digit levels**, indicating resilient demand momentum. ## C. Volume vs. Price Impact * **Volume-Driven Expansion:** Partnered portfolio delivered positive volume growth despite headwinds, reflecting sustained brand traction and distribution effectiveness. ## D. OAD Portfolio Performance * **Resilient Portfolio Performance:** Emcure’s cardio and OAD portfolio achieved single-digit growth, maintaining momentum amid organizational transitions. ## E. Treatment Initiation Trends * **Growth Catalyzed by Access & Awareness:** Insulin initiation and intensification efforts in **Tier 2 and Tier 3 cities**, powered by digital outreach, are expanding treatment penetration. * **Earlier Diagnosis Driving Demand:** Improved screening is fueling earlier treatment starts, boosting utilization of both **OADs and insulin** across the continuum of care. --- # 7. Risks & Regulatory Factors ## A. Supply Chain Disruptions * **No Material Supply Disruption:** Management confirms **adequate stock** of Lantus and uninterrupted supply continuity, despite isolated distribution delays in urban Maharashtra. * **Localized Distribution Glitch:** Perceived shortages attributed to a **one-off delay** in distributor-level restocking, not a systemic supply issue. * **Clinical Channel Feedback:** Concerns raised by a senior diabetologist reflect patient-level anecdotes rather than broad availability issues, with no impact on overall product access. --- # 8. Guidance & Outlook ## A. Key Figures *No significant quantitative financial metrics available for extraction.* ## B. 2026 Sales Stabilization * **Stabilization in Sight:** Partnership sales volatility expected to persist through 2026, with normalization anticipated by year-end following structured stock replenishment agreements. * **Underlying Growth Potential:** Management cites **double-digit growth** potential in core markets, excluding external disruptions, with continued expansion of partner channels. ## C. Long-Term Growth Targets * **Strategic Commitment:** Sanofi India reaffirms long-term India focus after **70-plus years** of operations, prioritizing growth in insulin and diabetes care. * **Optimal Growth Scenario:** Management asserts that in absence of partner-related disruptions, business performance would likely reflect **double-digit growth** trajectory. ## D. Dividend Expectations * **Dividend Timeline Confirmed:** Final dividend for FY26 pending approval at the **general assembly in May or June 2026**, following interim payout. * **Investor Sentiment Positive:** Retail investors commend Sanofi’s **consistent dividend policy** and investor-friendly approach, linking returns to sustained growth. ## E. Transformation Impact * **Transformation Year Complete:** 2024–2025 marked by major structural shifts, including **Consumer Health demerger** and key partnerships in Q1 2024 and July 2025, complicating performance comparability. * **Forward Focus:** Leadership prioritizes **growth, operational efficiency, partnership stabilization**, and full realization of transformation benefits to drive sustainable profitability.